Ottawa, June 18, 2015 – The Patented Medicine Prices Review Board (PMPRB) will hold a public pre-hearing conference in the matter of the price of the patented medicine Soliris and Alexion Pharmaceuticals Inc., the pharmaceutical company that exercises patent rights for Soliris and sells the medicine in Canada.
The purpose of the pre-hearing conference is to allow parties to identify or circumscribe the issues related to the hearing and resolve any other issues that may facilitate the conduct of the hearing.
Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria—a rare and life-threatening blood disorder characterized by excessive destruction of red blood cells—and Atypical Hemolytic Uremic Syndrome, a rare and life-threatening genetic disorder characterized by blood clots in small vessels.
When: Monday, June 22; Tuesday, June 23; and Wednesday, June 24, 2015
From 9:30 a.m. to 5:00 p.m. (EST)
Location: Hearing Room #1
333 Laurier Avenue West, 18th floor
Ottawa, Ontario
Media representatives are asked to please register in advance with the PMPRB’s Manager, Communications at 613-960-9728 or by e-mail at Sofie.McCoy-Astell@pmprb-cepmb.gc.ca. Instructions on attending the pre-hearing conference will be provided upon registration.
Please note that no audio or video recording of any kind will be permitted during the pre-hearing conference.
The Patented Medicine Prices Review Board protects and informs Canadians by ensuring the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.
-30-
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Sofie.McCoy-Astell@pmprb-cepmb.gc.ca
Follow us on Twitter: @PMPRB_CEPMB
